OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Values and ranges of input parameters in the analysis

Input parameter Value Range Source
Sensitizing mutation status in tissue (%)
Positive 84.6 83.7–87.5 [10, 17, 18]
Negative 5.4 1.5–6.3 [10, 17, 18]
Indeterminate 10.0 10.0–11.0 [16]
Sensitizing mutation status in plasma (%)
Positive 79.2 73.3–85.0 [10, 17, 18]
Negative 20.9 8.2–22.4 [10, 17, 18]
Complication of biopsy 6.0 4.3–6.8 [2022]
T790M status by tissue (%)
Positive 75.6 71.1–81.0 [5, 15, 19]
Negative 14.4 9.0–18.9 [5, 15, 19]
Indeterminate 10.0 10.0 [5, 15, 19]
T790M status by plasma (%)
Positive 65.9 61.0–73.2 [5, 15, 19]
Negative 34.1 26.8–39.0 [5, 15, 19]
Cost (KRW)
Biopsy procedure 676,066 494,836–857,296
Hospitalization due to complication 917,775 615,725–1,219,825
EGFR testing 131,505
Drug cost
First-generation TKI per day 33,149 24,950–45,810
First-line chemotherapy per cycle 596,132
Third-generation TKI per day 227,356
Second-line chemotherapy per cycle 926,609
Subsequent treatment per cycle 830,264

Abbreviations: EGFR, epidermal growth factor receptor; KRW, Korean won; TKI, tyrosine kinase inhibitor.

Ann Lab Med 2023;43:605~613 https://doi.org/10.3343/alm.2023.43.6.605

© Ann Lab Med